Results 181 to 190 of about 183,644 (348)

The Third Cytoplasmic Loop of the Angiotensin II Type 1 Receptor Exerts Differential Effects on Extracellular Signal–Regulated Kinase (ERK1/ERK2) and Apoptosis via Ras- and Rap1-Dependent Pathways [PDF]

, 2000
Judith Haendeler, Mari Ishida, László Hunyady, Bradford C. Berk   +3 more
openalex   +1 more source

Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats

Hepatology, 2001
H. Yoshiji, S. Kuriyama, J. Yoshii, Y. Ikenaka, R. Noguchi, T. Nakatani, H. Tsujinoue, H. Fukui   +7 more
semanticscholar   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Unlocking the potential of targeting the angiotensin II type 1 receptor in cancer. [PDF]

Oncogene
Butcher DR, Parris CN, Crichton SJ, Dempsey FC, Al-Ali HN.   +4 more
europepmc   +1 more source

Atrial Electrical Remodeling in Mice With Cardiac-Specific Overexpression of Angiotensin II Type 1 Receptor. [PDF]

J Am Heart Assoc, 2022
Demers J, Ton AT, Huynh F, Thibault S, Ducharme A, Paradis P, Nemer M, Fiset C.   +7 more
europepmc   +1 more source

Angiotensin II receptor, type 1 (AGTR1; AT1) [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Angiotensin II type 1 receptor localizes at the blood-bile barrier in humans and pigs. [PDF]

Histochem Cell Biol, 2022
Pryymachuk G, El-Awaad E, Piekarek N, Drebber U, Maul AC, Hescheler J, Wodarz A, Pfitzer G, Neiss WF, Pietsch M, Schroeter MM.   +10 more
europepmc   +1 more source

Effect of systemic administration of valsartan, an angiotensin II type 1 receptor blocker, on retinal circulation in healthy humans [PDF]

, 2008
Taiji Nagaoka, Atsushi Takahashi, Eriko Sato, Harumasa Yokota, Naohiro Izumi, Akitoshi Yoshida   +5 more
openalex   +1 more source

Angiotensin II type 1 receptor (AGTR1; AT1R) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source